ReviewJournal of frailty, sarcopenia and falls2025
The Influence of Muscle Morphology on Oncological Outcomes: A Review.
Review in Journal of frailty, sarcopenia and falls, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Limited agreement between nutritional screening tools and CT-defined body composition alterations in hospitalized cancer patients: a real-world analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a common disease with significant impact on patients and society. Cancer and oncological treatment can negatively affect muscle, and muscle health impacts oncologic outcomes. This review studied the effect of different muscle parameters on oncologic outcomes. A systematic search was performed until April 2023. Parameters included were muscle thickness, cross-sectional area, skeletal muscle index, skeletal muscle mass, pennation angle, fascicle length, muscle density, echo intensity and elastography. Imaging methods included were computerized tomography, magnetic resonance imaging, ultrasound and dual-energy X-ray absorptiometry. Outcome parameters assessed were survival, chemotoxicity, surgical outcome, treatment response, duration of hospitalization, and quality of life. This review included 117 articles. Individuals with reduced skeletal muscle index or muscle density had lower survival rates, higher chemotoxicity and surgical complications, more hospitalizations, less treatment response and lower quality of life. Reduced muscle quantity and quality can impact oncological outcomes, either through primary or secondary sarcopenia. These findings warrant the need for holistic assessment by using comprehensive geriatric assessment to establish a correct treatment dosage. These results also suggest a beneficial effect of exercise and nutritional support. Further research can be useful to better understand the underlying mechanisms and optimize specific treatments for muscle in oncological patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.